2012 Highlights from HIV11 Congress

Welcome to the Highlights from HIV11 Congress resource page. This is your central portal for information presented at the Eleventh International Congress on Drug Therapy in HIV Infection, including novel treatment options, breaking clinical trials and guideline updates. In addition to breaking news, this resource page features onsite video interviews with leading experts to get their reactions on some of the clinical updates and news presented at the conference, and what implications they have for the future.


Video Coverage 

 

Exhaustion of HIV therapies expected for some patients

GLASGOW — As treatment options are exhausted in the coming years, a substantial difference in life expectancy between people living with HIV and the general population is expected —particularly for those with HIV acquired at a younger age or for those who are highly treatment-experienced, according to presenter James Jansson, research assistant in the surveillance and evaluation program of public health at The Kirby Institute in Australia.

A model aimed at projecting the future life expectancy of people living with HIV in resource-rich settings estimated that the median time until exhaustion of currently available treatment options is 43.4 years and that 10% will use up all currently available ART options after only 22.6 years. More »

News Coverage from HIV11 Congress

  • Rilpivirine combo not inferior to efavirenz combo in HIV

  • November 15, 2012
  • GLASGOW — A new combination tablet including rilpivirine, emtricitabine and tenofovir was non-inferior to the existing combination tablet including efavirenz, emtricitabine and tenofovir, according to results from the STaR study presented here at the HIV11 Congress. More »
  • More coinfected patients receiving treatment for acute HCV

  • November 14, 2012
  • GLASGOW — Treatment incidence for acute hepatitis C virus among coinfected patients increased from 1998 to 2007 and appears to be more frequent in patients with higher CD4 counts and lower HIV-RNA, which is in line with current guidelines, according to data presented here. More »
  • CHER trial: Virologic response achieved in infants with early ART

  • November 13, 2012
  • GLASGOW — Six-year follow-up data on the Children with HIV Early Antiretroviral Therapy trial presented here suggest that a significant virologic response was obtained in infants assigned to ART at an early age — treatment interruption did not adversely affect virological outcomes. More »
  • Continued surveillance needed to monitor global HIV drug resistance

  • November 13, 2012
  • GLASGOW — Global HIV drug-resistance surveillance data — initiated by WHO in 2004 after a 26-fold increase in ART use in low- and middle-income countries — indicate an overall increase in HIV drug resistance, particularly with non-nucleoside reverse transcriptase inhibitors
    in Africa. More »
  • PrEP in Europe: New research under way

  • November 13, 2012
  • GLASGOW — Despite major advances in HIV therapy, the number of new HIV infections in Europe remains high, and new prevention strategies must be assessed to curb the incidence of HIV infection, Jean-Michel Molina, MD, of Saint-Louis Hospital and University of Paris, said here at the HIV11 Congress. More »

[X]